ReviewJournal of pain research2026
Evolving Concepts in the Diagnosis and Management of Fibromyalgia: A Moving Target.
Review in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia (FM) is a chronic, multifactorial pain syndrome involving widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction, significantly reducing the quality of life of patients. FM is classified under MG30.01, representing chronic widespread pain, within the broader classification of chronic primary pain according to the International Classification of Diseases, 11th Revision. FM has a complex, multifactorial pathophysiology involving peripheral and central mechanisms that contribute to its marked clinical heterogeneity. Currently, FM is diagnosed primarily through clinical assessment using widely accepted criteria, such as the American College of Rheumatology criteria, most recently revised in 2016, which evolved from the widely used 2010/2011 diagnostic framework. A thorough differential diagnosis is required to distinguish FM from a wide range of rheumatic, neurological, endocrine, psychiatric, and other medical disorders. FM management requires a multidisciplinary approach. Non-pharmacological interventions, including patient education, exercise (eg, aerobic and resistance training), and psychological therapies, such as cognitive behavioral therapy, are recommended as first-line treatments. Pharmacological therapies, including pregabalin, duloxetine, milnacipran, and cyclobenzaprine, are Food and Drug Administration-approved and provide clinically meaningful benefits to patients with FM. Although tramadol may be considered, the use of other opioids is generally not recommended because of their limited efficacy and potential risks. Despite the availability of current diagnostic criteria and treatment options, achieving a consistent diagnosis and optimal outcomes in patients remains challenging. Therefore, this narrative review aims to provide a concise, updated, and clinically relevant overview of the current evidence regarding the pathogenesis, diagnosis, and multidisciplinary management of FM to improve diagnostic accuracy and support individualized patient management. Furthermore, future directions should prioritize improving diagnostic precision and developing mechanism-based interventions targeting the underlying pathophysiology of FM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.